Veriox® Platform for Wound Healing
Prevention/Treatment of localized drug-resistant wound infections
Pre-clinicalActive
Key Facts
Indication
Prevention/Treatment of localized drug-resistant wound infections
Phase
Pre-clinical
Status
Active
Company
About Armis Biopharma
Armis Biopharma is tackling the global antimicrobial resistance (AMR) crisis with its Veriox® platform, a proprietary topical antimicrobial/antitoxin. The technology aims to deliver high local concentrations of active agent with low systemic exposure, targeting a broad spectrum of pathogens including Gram-positive and Gram-negative bacteria, viruses, and fungi. The company is pre-revenue and in the preclinical development stage, focusing on creating products for wound care and surface decontamination to reduce infection severity and healthcare costs.
View full company profile